Skip to content

Supportive-Expressive and Emotion-Focused Treatment for Depression

Investigating Mechanisms of Change in Supportive-Expressive vs. Emotion-Focused Treatment of Depression Using a Personalized Treatment Approach: The Case of the Theories of Weakness vs. Strength

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04576182
Acronym
SETEFT
Enrollment
124
Registered
2020-10-06
Start date
2020-11-29
Completion date
2027-05-31
Last updated
2026-05-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Depressive Disorder

Keywords

Psychotherapy, Mechanism of change, supportive-expressive treatment, Emotion-Focused Therapy, Psychodynamic psychotherapy, Insight, emotional processing

Brief summary

This study will explore the mechanisms of change that are activated when individuals receive a treatment that targets their weakness and the mechanisms activated when the treatment capitalize on their strength. Patients will be assigned to one of two types of psychotherapies in treating people with a major depression disorder, expressive-supportive vs. emotion-focused treatment. Their ability to benefit from treatment based on their pre-treatment levels of insight and emotional processing will be examined. This is a four-month protocol, with a 2 year follow up period.

Detailed description

One hundred and twenty-four patients suffering from major depressive disorder will be randomized to participate in 16 sessions of either supportive-expressive therapy or emotion-focused therapy. The two treatments are theorized to differ in their main mechanism of change: supportive-expressive therapy places emphasis on insight as its main mechanism of change, and emotion-focused therapy places emphasis on emotional processing as its main mechanism of change. Both can serve as strength- or weakness-focused treatments, based on the patient's baseline levels of insight and emotional processing. Importantly, this study will employ multiple complementary methods, which will include session-by-session self-report questionnaires from both patient and therapist, as well as interdisciplinary measures based on hormonal and acoustic measures, cognitive tasks, clinician interviews, and behavioral coding systems to complement the self-report measures. In addition, prior the beginning of treatment patients will complete diaries via mobile survey application. The findings will contribute to the research on personalized mechanisms of change and can help clinicians focus on more efficient treatment delivery, adapted to given subpopulations of patients, according to their strengths and weaknesses. If a mechanism most likely to stimulate change for a subpopulation is identified, a corresponding treatment can be chosen that is most likely to activate that particular mechanism and by that improve the rate of patients' respondent to treatment.

Interventions

Sixteen weeks of a time-limited psychodynamic therapy adapted for depression that includes the use of expressive techniques, such as interpretation, confrontation, clarification and the use of supportive techniques, such as affirmation and empathic validation. This treatment postulates insight as its core mechanism of change.

BEHAVIORALEmotions-Focused treatment

Sixteen weeks of a brief experiential therapy for depression that combine client-centered relational elements (unconditional positive regard, congruence, and empathy) with marker-guided experiential interventions designed to facilitate and deepen emotional processing and emotion regulation.

Sponsors

University of Haifa
Lead SponsorOTHER
Israel Science Foundation
CollaboratorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Masking description

Double Blind (participants, outcome assessor)

Intervention model description

A randomized controlled trial

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Meeting major depressive disorder diagnostic criteria using the structured clinical interviews for Diagnostic and Statistical Manual of Mental Disorders-5 and scoring more than 14 on the 17-item Hamilton rating scale for depression at two evaluations (one week apart) (Hamilton, 1967). * If on medication, patients' dosage must be stable for at least three months prior to entering the study, and they must be willing to maintain stable dosage for the duration of treatment * Age between 18 and 65 * Hebrew language fluency * Provision of written informed consent.

Exclusion criteria

* Current risk of suicide or self-harm * current substance abuse disorders * current or past schizophrenia or psychosis, bipolar disorder, or severe eating disorder requiring medical monitoring * history of organic mental disease * currently in psychotherapy

Design outcomes

Primary

MeasureTime frameDescription
Weekly change in Hamilton rating scale for depression (HRSD)up to 16 weeks.A 17-item clinically administered measure assessing the severity of depression. Higher scores indicate worse outcome.

Secondary

MeasureTime frameDescription
Weekly change in Beck Depression Inventory (BDI)up to 16 weeksA 21-item, self-rated scale that evaluates key symptoms of depression. Higher scores indicate worse outcome.
Weekly change in Outcome Questionnaire (OQ)up to 16 weeksA 30 items self-report measure designed to assess patient therapy outcomes on three primary dimensions: (a) subjective discomfort, (b) interpersonal relationships, and (c) social role performance. Higher scores indicate worse outcome.
Trajectories of change in Inventory of Interpersonal Problems (IIP-32)At intake and 6 times during the treatment (weeks 1, 2, 4, 8, 12, 16)A 32-item self-report measure designed to assess interpersonal problems. Each item is rated in terms of how distressing the problem is for the individual on a scale ranging from 0 (not at all) to 4 (extremely). Higher scores indicate worse outcome.
trajectories of change in Quality of Life Enjoyment and Satisfaction- Short Version (Q-LES-Q)At intake and 6 times during the treatment (weeks 1, 2, 4, 8, 12, 16)Quality of Life Enjoyment and Satisfaction Scale. Higher scores indicate better outcome.

Countries

Israel

Contacts

CONTACTSigal Zilcha-Mano, PhD
sigalzil@gmail.com972-8249047

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 8, 2026